Emerg Med J. 2013 Jul;30(7):597-9. doi: 10.1136/emermed-2013-202853.3.
A short-cut review was carried out to determine whether protein S100B either alone or incorporated into clinical guidelines could be used to identify accurately those adults with mild head injury who had significant brain trauma. Thirty-five papers were found using the reported searches, of which nine presented the best evidence to answer the clinical question. The author, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses of those best papers are shown in table 3. It is concluded that while S100B is a sensitive test for traumatic brain injury, there is no evidence to determine whether it adds value to any current clinical guidelines.
一项快捷回顾旨在确定 S100B 蛋白是否可单独使用或纳入临床指南,以准确识别那些轻度头部损伤但存在显著脑损伤的成年人。通过报告的检索共发现 35 篇论文,其中 9 篇为回答临床问题提供了最佳证据。表 3 显示了这些最佳论文的作者、日期和出版国家、研究的患者群体、研究类型、相关结局、结果和研究弱点。结论是,虽然 S100B 是一种用于外伤性脑损伤的敏感测试,但没有证据表明它对任何现行临床指南具有附加价值。